RigsHeart 🫀🚨

Official account of the Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Denmark

[RigsHeart 🫀🚨 @RigsHeart]

‼️🚨 RIGSHEART is on LinkedIn! 📢 🙌🏼

Follow for the lastest cardiovascular research updates and publications from Rigshospitalet! 🫀

🔗 https://t.co/VKalmgZrH2

[RigsHeart 🫀🚨 @RigsHeart]

📢Just out by @Casarini_E et al. in @ResusJournal 🫀

Don't miss this important read on sex differences in OHCA-survivors: 📑https://t.co/LAwdKQFufk

[RigsHeart 🫀🚨 @RigsHeart]

🎓 PhD Defence Announcement!

Join us as Dr. Elvira Silajdzija defends her PhD on November 14, 2025:

🌟 Hypertrophic Cardiomyopathy: Clinical Trajectories in Probands and Relatives, Strategies to Optimize Follow-Up, and the Impact of Outflow Tract Obstruction 🌟

📍Adolf Hannover Auditorium, Building 20, Panum, Blegdamsvej 3B, 2200 Copenhagen N

🗓️ 14:00-17:00

We look forward to celebrating this milestone — all are welcome to attend 🥳

#PhDDefense #Research

[RigsHeart 🫀🚨 @RigsHeart]

Link: https://t.co/MdUdBc97jE

[RigsHeart 🫀🚨 @RigsHeart]

🗣️ New in EP Europace @EuropaceEiC

A new study using UK Biobank shows that sVCAM-1, an inflammatory biomarker 🧪, was associated with #AFib and #HF 🫀, independently of known biomarkers of HF and inflammation.

➡️ Potential to refine risk assessment and early monitoring — now needs clinical validation🏥.

#cardiotwitter #Epeeps @SZDiederichsen @Oliver_B_Vad

[RigsHeart 🫀🚨 @RigsHeart]

Full paper:
https://t.co/rzbRXV887e

[RigsHeart 🫀🚨 @RigsHeart]

Just out in @JACCJournals 🥳🥳🥳

🗣️ New analysis from #LOOPstudy
Screening for #AFib 🫀 with implantable loop recorders reduced #stroke 🧠 only in individuals with high polygenic risk for AF 🧬 — but not in those with low genetic risk.

➡️ Genetics #PRS may help target who actually benefits from AF screening❗️

#AFib #Genomics #CardioTwitter

[RigsHeart 🫀🚨 @RigsHeart]

‼️🚨 RIGSHEART is on LinkedIn! 📢 🙌🏼

Follow for the lastest cardiovascular research updates and publications from Rigshospitalet! 🫀

🔗 https://t.co/VKalmgZrH2

[CTCPR Trials & CIRL @CTCPR_]

🔬 @CTCPR_ FLUNITY-HD study, published in @TheLancet, reveals that the High-Dose influenza vaccine provides superior protection against hospitalisations compared to the conventional Standard-Dose.

Nearly 500,000 participants aged 65+ were individually randomized — the first study powered to demonstrate improved prevention of severe outcomes beyond just influenza.

Discover this new research, Effectiveness of high-dose influenza vaccine against hospitalisations in older adults: the FLUNITY-HD individual-level pooled analysis: https://t.co/kXU06PxhPU

#CTCPR #InfluenzaPrevention

@TorBiering
@niklasdj1
@KiraJanstrup
@McLevant
@Jhdeprez
@CopCard
@RigsHeart
@HGHHjerte
@Stenodiabetes

[Oliver Bundgaard Vad @Oliver_B_Vad]

📢 Excited to share our newest publication in the EHJ!

🫀 In >26k individuals without prior AF or HF, 1 in 7 had markers of atrial cardiomyopathy.
↗️ Markers were linked with higher rates of AF, HF, and stroke.

Now online:
🔗https://t.co/C0VwwmAbD1

@ESC_Journals @RigsHeart

[RigsHeart 🫀🚨 @RigsHeart]

💡 Can ICDs prevent death in non-ischemic HF regardless of cause ❓

⚡An extended DANISH follow-up trial assessed this
🔎n=1116, median 9.5y

🔴76% idiopathic HF, 24% non-idiopathic (valvular, hypertensive, other)
🔴ICD vs usual care: no reduction in all-cause death (idiopathic HR 0.89; non-idiopathic HR 0.86)
🔴ICD lowered sudden cardiovascular death, effect independent of HF etiology (Pinteraction ~1)

🔗https://t.co/SzQn44TLhC

@adelinayafasova @SeikoDoi @JawadHButt

[CTCPR Trials & CIRL @CTCPR_]

🌍 New insights by @Espersen_C and colleagues @CTCPR_ | @CircAHA

Cardiovascular disease (CVD) affects 11% of the Danish population and remains the second leading cause of death, responsible for ≈12,000 deaths annually. Despite Denmark’s universal healthcare, social and geographic inequalities persist, highlighting the need for targeted prevention and system-level solutions.

Denmark’s strong registry infrastructure and public health initiatives provide unique opportunities to monitor, evaluate, and improve cardiovascular care. Continued focus on education, equitable access, and innovative prevention strategies is crucial to reduce disparities and improve outcomes. Public initiatives, such as the Heart Runner program, anti-smoking policies, and accessible cardiac rehabilitation, are already making a difference.

Published in Circulation Global Rounds, American Heart Association, Inc.
🔗 Read full article: https://t.co/Ts4kKuWyPp

[RigsHeart 🫀🚨 @RigsHeart]

📢🫀 Just out by @CheeWoonLim1, @schophuus , @Jani_MD_ et al.:

In a nationwide study assessing school performance in children with congenital heart disease (CHD) (n = 10 717) compared to controls (n = 229 738):

💡Children with CHD ranked 📉 than controls [0.47 (95% confidence interval (CI): 0.46–0.48) vs. 0.50 (95% CI: 0.50–0.50)]

💡Higher risk of failure ⬆️(27% vs. 19%)

💡School performance worsened over time ⏳

👉CHD impacts school performance across all severities - closer surveillance and tailored support are needed

🔗Read more:
https://t.co/38tKaxmA88

[RigsHeart 🫀🚨 @RigsHeart]

🏆Congratulations to @AstridDuusMik who has won the Young Investigator Award in Interventional Cardiology at #ESCcongress2025!🥇🫀 Her study shows how early systolic blood pressure modifies the survival benefit of mAFP-treatment in infarct-related cardiogenic shock ‼️

📖 The paper was simultaneously published in @JAMACardio: https://t.co/8280vLji5u
Editorial: https://t.co/gVPssSg45A #DanGerShock #cardiogenicshock

[Lucas Xing @lucas_yxing]

🌟Honored to present our individual-level meta-analysis on #AFib screening in Late-Breaking Science at #ESCcongress2025🇪🇸

Many thanks to all participating study centers and EU #Horizon2020🇪🇺

Grateful to @escardio 🫀 for such a unique opportunity for knowledge sharing!

#Epeeps

[RigsHeart 🫀🚨 @RigsHeart]

#ESCcongress2025 🫀

[RigsHeart 🫀🚨 @RigsHeart]

With SimPub in @NEJM :
https://t.co/dFLCHdPsHV

[RigsHeart 🫀🚨 @RigsHeart]

🚨 @Rigsheart in Late Breaking Science 🚨

Long-term outcomes of the DanGer Shock
- by Jacob Eifer Møller

📍 Budapest
🗓️ 11:15

A highlight you won’t want to miss at #ESCCongress2025 🫀✨

[Søren Zöga Diederichsen @SZDiederichsen]

Here's a link to the simultaneous publication
https://t.co/myDx2QHAeE

An understudied but important subject: how doesscreening and extra diagnoses impact quality of life measures